Ocuphire Pharma
summary of ophthalmic solution trial results post dose bree nea mild | Ocuphire Pharma
Company
Deck Type
Deck date
November 2023
Slide
35 of 42
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Investor Presentation
August 2023
summary of trial results | Ocuphire Pharma
Investor Presentation
May 2023
summary of trial results | Ocuphire Pharma
Related slides by other companies
Nuvectis Pharma
Investor Presentation
August 2023
phase underway fast track designation | Nuvectis Pharma
Nuvectis Pharma
Investor Presentation
July 2023
phase underway fast track designation | Nuvectis Pharma
ATAI
Investor Presentation
October 2022
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the preparations to initiate the phase comparative study to bridge from to a subcutaneous formulation continue phase study will be completed this year randomized establish human proof of concept | ATAI
Aeglea BioTherapeutics
Investor Presentation
February 2022
primary met marked and sustained reduction in plasma arginine | Aeglea BioTherapeutics
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io